Related references
Note: Only part of the references are listed.Combined Targeting of PARG and Wee1 Causes Decreased Cell Survival and DNA Damage in an S-Phase-Dependent Manner
Lebaron C. Agostini et al.
MOLECULAR CANCER RESEARCH (2021)
Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
William H. Gmeiner et al.
MOLECULAR CANCER THERAPEUTICS (2021)
PARP and PARG inhibitors in cancer treatment
Dea Slade
GENES & DEVELOPMENT (2020)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience
Luigi Cavanna et al.
ONCOTARGETS AND THERAPY (2019)
Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer
Aditi Jain et al.
CANCER RESEARCH (2019)
Targeting Topoisomerase I in the Era of Precision Medicine
Anish Thomas et al.
CLINICAL CANCER RESEARCH (2019)
AACR Cancer Progress Report 2019: Transforming Lives Through Innovative Cancer Science
Rajarshi Sengupta et al.
CLINICAL CANCER RESEARCH (2019)
Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition
Teena Dhir et al.
MOLECULAR CANCER RESEARCH (2019)
Protein PEGylation for cancer therapy: bench to bedside
Vijayalaxmi Gupta et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2019)
Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative
Michael J. Pishvaian et al.
CLINICAL CANCER RESEARCH (2018)
Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models
Talia Golan et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition
Chinnadurai Mani et al.
NEOPLASIA (2018)
Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions
Aurelien Lambert et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors
Saswati N. Chand et al.
CANCER RESEARCH (2017)
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Giovanni Y. Di Veroli et al.
BIOINFORMATICS (2016)
The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence
William H. Gmeiner et al.
FUTURE ONCOLOGY (2016)
F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death
William H. Gmeiner et al.
FUTURE ONCOLOGY (2016)
Immunodetection of human topoisomerase I-DNA covalent complexes
Anand G. Patel et al.
NUCLEIC ACIDS RESEARCH (2016)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
Julio C. Morales et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2014)
Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors
William H. Gmeiner et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage
Benu Brata Das et al.
NUCLEIC ACIDS RESEARCH (2014)
ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays
Camilo Guzman et al.
PLOS ONE (2014)
The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells
Timothy S. Pardee et al.
ONCOTARGET (2014)
Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity
Jamie Jennings-Gee et al.
EXPERIMENTAL HEMATOLOGY (2013)
TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs
Shar-yin N. Huang et al.
NUCLEIC ACIDS RESEARCH (2013)
Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity
Timothy S. Pardee et al.
BLOOD (2012)
Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
Anand G. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Koh Miura et al.
Cancers (2010)
Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin
G. Codacci-Pisanelli et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2008)
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer:: A model for patient classification to aid fluoropyrimidine therapy
Jonathan R. Brody et al.
CANCER RESEARCH (2006)
A proposed clinical test for monitoring fluoropyrimidine therapy - Detection and stability of thymidylate synthase ternary complexes
Jonathan R. Brody et al.
CANCER BIOLOGY & THERAPY (2006)
Novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes
ZY Liao et al.
CANCER RESEARCH (2005)
Enhanced DNA-directed effects of FdUMP[10] compared to 5FU
WH Gmeiner et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2004)
α-fluoro-β-alanine:: Effects on the antitumor activity and toxicity of 5-fluorouracil
SS Cao et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
